US 11,999,765 B2
Neuroactive steroids and their methods of use
Maria Jesus Blanco-Pillado, Arlington, MA (US); Francesco G. Salituro, Marlborough, MA (US); and Marshall Lee Morningstar, Framingham, MA (US)
Assigned to Sage Therapeutics, Inc., Cambridge, MA (US)
Filed by SAGE THERAPEUTICS, INC., Cambridge, MA (US)
Filed on Jun. 13, 2023, as Appl. No. 18/334,189.
Application 18/334,189 is a continuation of application No. 17/311,056, previously published as PCT/US2019/064692, filed on Dec. 5, 2019.
Claims priority of provisional application 62/775,470, filed on Dec. 5, 2018.
Prior Publication US 2023/0322848 A1, Oct. 12, 2023
Int. Cl. C07J 43/00 (2006.01); C07J 41/00 (2006.01)
CPC C07J 43/003 (2013.01) [C07J 41/0044 (2013.01); C07J 41/0094 (2013.01)] 21 Claims
 
1. A compound of Formula (I-v):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein
each of R1a, R1b, R2a, R2b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R12a, R12b, and R19 is hydrogen;
each of R3a, R18, and RY is methyl;
each RD is hydrogen;
q is 0, 1, 2, 3, 4, or 5; and
R55c is

OG Complex Work Unit Chemistry
wherein
each Ra is independently hydrogen, halogen, —CN, —ORD4, —N(RD4)2, or substituted or unsubstituted C1-6 alkyl, each RD4 is independently hydrogen or substituted or unsubstituted C1-6 alkyl, and
p is 0, 1, or 2.